☆ 4.5 Review

Primary biliary cholangitis: Epidemiology, prognosis, and treatment

HEPATOLOGY COMMUNICATIONS (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Response to Ursodeoxycholic Acid May Be Assessed Earlier to Allow Second-Line Therapy in Patients with Unresponsive Primary Biliary Cholangitis

Guilherme Grossi Lopes Cancado et al.

Summary: This study aims to determine whether well-validated response criteria can accurately identify patients who may benefit from early addition of second-line therapies after six months of treatment with UDCA. The results show that non-response to UDCA can be properly identified using different criteria, especially in patients with advanced PBC or high baseline liver enzyme levels.

DIGESTIVE DISEASES AND SCIENCES (2023)

Add to Collection

Article Gastroenterology & Hepatology

Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion

Chunmei Yang et al.

Summary: This study aimed to develop a new criterion to identify primary biliary cholangitis (PBC) patients who do not respond to ursodeoxycholic acid (UDCA) treatment at an early stage. The Xi'an criterion, which evaluates UDCA response at 1 month, showed a high capacity to distinguish high-risk PBC patients.

HEPATOLOGY INTERNATIONAL (2023)

Add to Collection

Review Medicine, General & Internal

Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists

John Sheppard et al.

Summary: Dry eye disease is a multifactorial disorder characterized by tear film imbalance, which can lead to inflammation and damage of the ocular surface. It affects 5% to 50% of the worldwide population and can be caused by various factors such as ocular and systemic diseases, medications, and environmental conditions. The management of this chronic disease involves both pharmacologic and nonpharmacologic interventions, with primary care clinicians playing a crucial role in diagnosis, education, and referral. It is important for healthcare professionals to be aware of the etiology and treatment options of dry eye disease.

ANNALS OF MEDICINE (2023)

Add to Collection

Article Gastroenterology & Hepatology

GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus

Cynthia Levy et al.

Summary: GLIMMER evaluated the dose-response, efficacy, and safety of linerixibat in the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC). The study found that linerixibat did not show significant difference in itch reduction compared to placebo in the primary intent-to-treat analysis, but it demonstrated a significant dose-dependent reduction in itch in the per protocol population. A well-tolerated dose was identified for Phase 3 investigation in the treatment of cholestatic pruritus in PBC.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Add to Collection

Article Pharmacology & Pharmacy

Maralixibat: First Approval

Matt Shirley

Summary: Maralixibat, developed by Mirum Pharmaceuticals, is an IBAT inhibitor for rare cholestatic liver diseases. It has received its first approval in the USA for treating cholestatic pruritus in ALGS patients, and is undergoing regulatory review in Europe and clinical development for other conditions in various countries.

DRUGS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study

Kosuke Matsumoto et al.

Summary: The study identified that poor environmental hygiene in childhood (vault toilets and unpaved roads) and chronic exposure to chemicals (smoking and hair dye use) are likely risk factors for the development of PBC in Japan.

JOURNAL OF GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis

Binu John et al.

Summary: In this large cohort, AMA-negative PBC cirrhosis was associated with similar rates of overall or liver-related death, HCC or decompensation compared with AMA-positive disease.

LIVER INTERNATIONAL (2022)

Add to Collection

Article Gastroenterology & Hepatology

Anti-mitochondrial Antibody-Negative Primary Biliary Cholangitis Is Part of the Same Spectrum of Classical Primary Biliary Cholangitis

Guilherme Grossi Lopes Cancado et al.

Summary: AMA-negative PBC patients in a large non-white admixed Brazilian cohort are similar to their AMA-positive counterparts with subtle differences observed in clinical and laboratory features, such as younger age at onset, earlier onset of first symptoms, higher frequency of type 2 diabetes, and differences in certain biochemical markers.

DIGESTIVE DISEASES AND SCIENCES (2022)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases

Keith D. Lindor et al.

HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis

Surain B. Roberts et al.

Summary: In a diverse Canadian cohort of PBC patients, Indigenous Canadians have poorer liver transplant-free and event-free survival compared to White patients. They are more likely to have a clinical event before diagnosis and present with higher liver function test indicators, which persist during follow-up.

HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis

Andreas E. Kremer et al.

Summary: The study found that seladelpar treatment for 1 year in PBC patients led to significant improvement in itching symptoms, quality of life, and biochemical markers. This suggests that seladelpar has the potential to address key unmet needs in PBC patients as a single agent.

LIVER INTERNATIONAL (2022)

Add to Collection

Article Gastroenterology & Hepatology

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Christopher L. Bowlus et al.

Summary: This study examined the efficacy and safety of seladelpar in patients with primary biliary cholangitis (PBC). The results showed that seladelpar significantly improved biochemical markers of cholestasis and inflammation, and the improvements were maintained or improved after dose escalation at 52 weeks. The treatment was safe and not associated with worsening pruritus.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

Christophe Corpechot et al.

Summary: In the largest ever study of LSM in patients with PBC, LSM assessed by VCTE improves prediction of survival beyond biochemical response, established prognostic scores, and age categories, independent of time. LSM can reasonably be regarded as a useful prognostic marker and a potential surrogate endpoint in PBC clinical trials.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Primary Biliary Cholangitis in Males Pathogenesis, Clinical Presentation, and Prognosis

Mina Shaker et al.

Summary: PBC, although more prevalent in females, has shown to be more common in males than previously believed. Men tend to present at a later stage of the disease and have a higher risk of death or transplantation, even after adjusting for various factors. There is a need for greater research and education to raise awareness and improve early detection among males with PBC.

CLINICS IN LIVER DISEASE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Autoantibodies in Primary Biliary Cholangitis

Kristel K. Leung et al.

Summary: Testing for autoantibodies is crucial for diagnosing PBC, evaluating related disease processes, and identifying potential prognostic factors. Further characterization of autoantibody profiles in PBC will contribute to our understanding of the pathophysiological mechanisms, as well as provide new insights into risk stratification and therapeutic targets.

CLINICS IN LIVER DISEASE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Liver Transplantation for Primary Biliary Cholangitis

Eric F. Martin

Summary: The number of liver transplantation for primary biliary cholangitis (PBC) has decreased over the years, but it remains an important and curative option for progressive PBC patients. Recent studies from the Global PBC Study Group have provided valuable insights into the changes in PBC before and after liver transplantation.

CLINICS IN LIVER DISEASE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

C. Fiorella Murillo Perez et al.

Summary: This study demonstrates that PBC patients treated with OCA in a trial setting have better transplant-free survival compared to the external control group, and OCA can reduce the levels of biomarkers associated with adverse clinical outcomes.

GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis

Alessio Gerussi et al.

Summary: The study demonstrated that serum GGT levels are associated with prognosis in patients with PBC, particularly for those requiring liver transplantation or facing liver-related death. A GGT level higher than 3.2-fold the upper limit of normal was identified as a risk marker for interventions in high-risk patients.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis

Yamini Natarajan et al.

Summary: The risk factors for hepatocellular carcinoma (HCC) in patients with primary biliary cholangitis (PBC) are not clear, but cirrhosis and male gender are shown to be significant factors in increasing HCC incidence. Further studies are needed to evaluate additional risk factors in this population and support current recommendations for HCC surveillance in PBC patients with cirrhosis.

DIGESTIVE DISEASES AND SCIENCES (2021)

Add to Collection

Article Gastroenterology & Hepatology

Use of Butorphanol as Treatment for Cholestatic Itch

Rachel Shireen Golpanian et al.

Summary: Butorphanol is a potential treatment option for cholestatic pruritus, showing clinically significant symptomatic improvement in some patients. However, it is associated with side effects such as somnolence, sedation, nausea, vomiting, and dizziness, indicating the need for further studies to better understand its effects on cholestatic itch.

DIGESTIVE DISEASES AND SCIENCES (2021)

Add to Collection

Article Gastroenterology & Hepatology

Gender and Racial Differences in Hospitalizations for Primary Biliary Cholangitis in the USA

Adeyinka Charles Adejumo et al.

Summary: The hospitalization rate and burden of primary biliary cholangitis (PBC) in the USA have increased disproportionately among females and Hispanics, with higher mortality rates observed among Blacks.

DIGESTIVE DISEASES AND SCIENCES (2021)

Add to Collection

Article Gastroenterology & Hepatology

Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis

Kristoffer Kjaergaard et al.

Summary: The study demonstrated that OCA increased the hepatic transport of conjugated bile acids in PBC patients, reducing the time hepatocytes are exposed to potentially toxic bile acids.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial

Elsemieke de Vries et al.

Summary: The study demonstrated the efficacy of bezafibrate in improving moderate to severe pruritus in patients with PSC and PBC, suggesting a potential role in reducing hepatobiliary injury.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude

Gwilym J. Webb et al.

Summary: A retrospective cohort study using UK primary care records found a positive correlation between a more northerly latitude and the incidence of PBC and AIH, but not PSC. Further research is needed to confirm and explain this association.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis

Tingting Lv et al.

Summary: The study estimated the incidence and prevalence of primary biliary cholangitis (PBC) worldwide, revealing significant regional differences with North America having the highest rates and Asia-Pacific the lowest. Additionally, there is an increasing trend in both PBC incidence and prevalence globally.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA

Jorn M. Schattenberg et al.

Summary: Elafibranor demonstrated good efficacy and safety in patients with PBC who had an incomplete response to ursodeoxycholic acid, significantly reducing levels of ALP and improving other disease activity markers.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Current understanding of primary biliary cholangitis

Atsushi Tanaka

Summary: Primary biliary cholangitis (PBC) is an autoimmune disease that mainly affects middle-aged women but also young women and men. It is characterized by degeneration and necrosis of intrahepatic biliary epithelial cells, with early diagnosis through detection of antimitochondrial antibodies and introduction of ursodeoxycholic acid as first-line treatment significantly improving clinical outcomes.

CLINICAL AND MOLECULAR HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis

Binu John et al.

Summary: In patients with PBC and well-compensated cirrhosis, male sex is associated with a higher risk of both death and liver-related death or transplantation.

HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Safety of fibrates in cholestatic liver diseases

Andres F. Carrion et al.

Summary: Fibrates are safe and well tolerated in patients with primary biliary cholangitis, with gastrointestinal and musculoskeletal adverse events being most commonly reported. Data on the safety of these agents for treatment of primary sclerosing cholangitis are limited.

LIVER INTERNATIONAL (2021)

Add to Collection

Review Oncology

Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases

Eirini I. Rigopoulou et al.

Summary: AILDs patients have a lower risk of developing HCC compared to other liver diseases, but still face an increased risk, influenced mainly by factors such as cirrhosis, age, gender, alcohol consumption, and treatment response. Personalized HCC risk prediction offers a significant advantage for patients at high and/or medium risk.

CANCERS (2021)

Add to Collection

Review Health Care Sciences & Services

Naltrexone for cholestatic itch: a systematic review

Fay Louise Murray-Brown

Summary: Oral naltrexone therapy has shown efficacy in relieving cholestatic itch, but caution should be exercised due to potential side effects, particularly opioid withdrawal-type reactions and recurrence of previous pain.

BMJ SUPPORTIVE & PALLIATIVE CARE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis

Binu V. John et al.

Summary: The study demonstrates that UDCA response is associated with a lower risk of hepatic decompensation, all-cause mortality or transplantation, and liver-related death or transplantation in predominantly male patients with cirrhosis, with the greatest benefit seen in those with portal hypertension.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naive Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach

Laura Cristoferi et al.

Summary: In the study of treatment-naive PBC patients, VCTE was found to accurately assess advanced fibrosis (AF) using LSM cutoffs of <= 6.5 and >11.0 kPa. LSM values between these cutoffs were not reliable, requiring liver biopsy for disease staging. BMI and liver biochemistry did not impact LSM measurements.

HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis

Atsushi Tanaka et al.

Summary: The addition of bezafibrate to ursodeoxycholic acid in patients with primary biliary cholangitis was associated with improved prognosis, as evident from a large retrospective cohort study. The combination therapy showed a significant decrease in all-cause and liver-related mortality or need for liver transplantation, indicating the potential benefits of this treatment approach.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study

Anna Reig et al.

Summary: The therapy of OCA and fibrates can improve hepatic biochemistry and the GLOBE score in patients with primary biliary cholangitis, and simultaneous treatment with both can also improve ALP levels.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Odevixibat: First Approval

Emma D. Deeks

Summary: Odevixibat, a small molecule inhibitor of the ileal bile acid transporter, has received approvals in the EU and USA for the treatment of PFIC and pruritus associated with PFIC. It is also in clinical development for other cholestatic diseases in various countries.

DRUGS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Recent advances in clinical practice: epidemiology of autoimmune liver diseases

Palak J. Trivedi et al.

Summary: Autoimmune liver diseases, including primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis, show meaningful changes in disease epidemiology with increasing incidence and prevalence in Europe, North America, and the Asia-Pacific region. Global variations exist in contemporary incidence rates, with age, sex, and race impacting clinical outcomes and the need for gastroenterology, hepatology, and organ transplant services.

GUT (2021)

Add to Collection

Article Gastroenterology & Hepatology

Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease

Helena Cortez-Pinto et al.

Summary: This study found a considerable proportion of patients with primary biliary cholangitis showed incomplete biochemical response to ursodeoxycholic acid (UDCA) treatment. Patients with cirrhosis, elevated levels of gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) at diagnosis were identified as being at higher risk for incomplete response. Early identification of patients at risk of incomplete response could improve treatment care and guide clinical decision-making.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)

Add to Collection

Article Gastroenterology & Hepatology

Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis

Jessica Katharine Dyson et al.

Summary: This study investigates the potential environmental contributors to autoimmune liver diseases (AILD) such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Significant spatial clustering of PBC and PSC patients was observed, with distinct risk profiles and associations with different environmental factors and socio-economic statuses identified. This suggests different triggers and alternative pathways determine the phenotypic expression of autoimmunity in the affected population.

JHEP REPORTS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis

Binu V. John et al.

Summary: This study investigated the effects of OCA treatment on hepatic decompensation and liver-related mortality or transplantation in patients with compensated PBC cirrhosis. The results showed that OCA use was associated with an increase in hepatic decompensation risk, but not with liver-related mortality or transplantation. Additional studies are recommended to further explore these findings.

HEPATOLOGY COMMUNICATIONS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis

Pierre-Antoine Soret et al.

Summary: The study demonstrated that triple therapy with UDCA, OCA, and fibrates can normalize biochemical liver tests and improve pruritus in patients with difficult-to-treat PBC.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

Daphne D'Amato et al.

Summary: The study evaluated the effectiveness and safety of Obeticholic acid (OCA) in PBC patients under real-world conditions, finding OCA to be effective in some patients intolerant to ursodeoxycholic acid, but with lower tolerability in cirrhotic patients. It was also observed that patients with overlap of autoimmune hepatitis and PBC responded well to OCA treatment.

JHEP REPORTS (2021)

Add to Collection

Review Gastroenterology & Hepatology

Managing cognitive symptoms and fatigue in cholestatic liver disease

Naw April Phaw et al.

Summary: Patients with cholestatic diseases, especially primary biliary cholangitis (PBC), may experience significant fatigue and cognitive symptoms. Despite the lack of effective pharmacological therapies, supportive approaches remain the mainstay of management for these symptoms. The impact of fatigue and cognitive symptoms on quality of life in PBC patients is profound, highlighting the need for further research and development of targeted therapies.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid

John E. Eaton et al.

HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase

Carla F. Murillo Perez et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Durable response in the markers of cholestasis through 5 years of open-label extension study of obeticholic acid in primary biliary cholangitis

F. Nevens et al.

DIGESTIVE AND LIVER DISEASE (2020)

Add to Collection

Review Gastroenterology & Hepatology

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

Aliya F. Gulamhusein et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

Add to Collection

Review Gastroenterology & Hepatology

Current and potential treatments for primary biliary cholangitis

Raj A. Shah et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis

Christophe Corpechot et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis

Minami Yagi et al.

LIVER INTERNATIONAL (2020)

Add to Collection

Article Gastroenterology & Hepatology

Hispanic Patients with Primary Biliary Cholangitis Have Decreased Access to Care Compared to Non-Hispanics

Atoosa Rabiee et al.

JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis

Surain B. Roberts et al.

HEPATOLOGY COMMUNICATIONS (2020)

Add to Collection

Review Gastroenterology & Hepatology

Fatigue in chronic liver disease: New insights and therapeutic approaches

Mark G. Swain et al.

LIVER INTERNATIONAL (2019)

Add to Collection

Article Gastroenterology & Hepatology

Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases

Keith D. Lindor et al.

HEPATOLOGY (2019)

Add to Collection

Review Gastroenterology & Hepatology

Obeticholic acid in primary biliary cholangitis: where we stand

Vignan Manne et al.

CURRENT OPINION IN GASTROENTEROLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis

Akira Honda et al.

HEPATOLOGY (2019)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial

George Dalekos et al.

JOURNAL OF HEPATOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis

Maren H. Harms et al.

JOURNAL OF HEPATOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis

Cumali Efe et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)

Add to Collection

Review Gastroenterology & Hepatology

Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis

Na Zeng et al.

HEPATOLOGY INTERNATIONAL (2019)

Add to Collection

Review Gastroenterology & Hepatology

Ursodeoxycholic acid in pregnancy?

Elsemieke de Vries et al.

JOURNAL OF HEPATOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response

Carla F. Murillo Perez et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)

Add to Collection

Article Gastroenterology & Hepatology

Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades

Maren H. Harms et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)

Add to Collection

Article Gastroenterology & Hepatology

Effects of Age and Sex of Response to Ursodeoxycholic Arid and Transplant-free Survival in Patients With Primary Biliary Cholangitis

Angela C. Cheung et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)

Add to Collection

Review Gastroenterology & Hepatology

Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis

Jennifer Y. Lee et al.

DIGESTIVE DISEASES AND SCIENCES (2019)

Add to Collection

Article Immunology

Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis in Young Patients: Analysis of the United Network for Organ Sharing Database

Amandeep Singh et al.

TRANSPLANTATION (2019)

Add to Collection

Article Gastroenterology & Hepatology

Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study

G. J. Webb et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Article Gastroenterology & Hepatology

PBC and related extrahepatic diseases

Annarosa Floreani et al.

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Symptoms of PBC - Pathophysiology and management

Amardeep Khanna et al.

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Risk stratification and prognostic modelling in primary biliary cholangitis

Jorn C. Goet et al.

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis

George Cholankeril et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment

Mei Lu et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Understanding and Treating Pruritus in Primary Biliary Cholangitis

Andres F. Carrion et al.

CLINICS IN LIVER DISEASE (2018)

Add to Collection

Article Gastroenterology & Hepatology

Chronic Complications of Cholestasis Evaluation and Management

David N. Assis

CLINICS IN LIVER DISEASE (2018)

Add to Collection

Article Gastroenterology & Hepatology

Current Status of Liver Transplantation for Primary Biliary Cholangitis

Maria T. Aguilar et al.

CLINICS IN LIVER DISEASE (2018)

Add to Collection

Article Gastroenterology & Hepatology

Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history

Carla F. Murillo Perez et al.

HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

Kris V. Kowdley et al.

HEPATOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

C. Corpechot et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Gastroenterology & Hepatology

Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

Marco Carbone et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome

Maren H. Harms et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Clinical Application of the GLOBE and United Kingdom-Primary Biliary Cholangitis Risk Scores in a Trial Cohort of Patients With Primary Biliary Cholangitis

Marco Carbone et al.

HEPATOLOGY COMMUNICATIONS (2018)

Add to Collection

Article Gastroenterology & Hepatology

Large-Scale Characterization Study of Patients With Antimitochondrial Antibodies but Nonestablished Primary Biliary Cholangitis

Geraldine Dahlqvist et al.

HEPATOLOGY (2017)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double-blind trial

Hiromitsu Kumada et al.

HEPATOLOGY RESEARCH (2017)

Add to Collection

Article Gastroenterology & Hepatology

Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch

Marcin Krawczyk et al.

LIVER INTERNATIONAL (2017)

Add to Collection

Article Surgery

Primary biliary cirrhosis has high wait-list mortality among patients listed for liver transplantation

Ashwani K. Singal et al.

TRANSPLANT INTERNATIONAL (2017)

Add to Collection

Review Gastroenterology & Hepatology

Extrahepatic Manifestations of Primary Biliary Cholangitis

Sara L. Chalifoux et al.

GUT AND LIVER (2017)

Add to Collection

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

Gideon M. Hirschfield et al.

JOURNAL OF HEPATOLOGY (2017)

Add to Collection

Article Gastroenterology & Hepatology

Identification and Characterization of Fenofibrate-Induced Liver Injury

Jawad Ahmad et al.

DIGESTIVE DISEASES AND SCIENCES (2017)

Add to Collection

Article Gastroenterology & Hepatology

Bile Acids in Cholestasis and its Treatment

Juan Pablo Arab et al.

ANNALS OF HEPATOLOGY (2017)

Add to Collection

Article Pharmacology & Pharmacy

A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis

Marina G. Silveira et al.

AMERICAN JOURNAL OF THERAPEUTICS (2017)

Add to Collection

Article Gastroenterology & Hepatology

Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes

A. C. Cheung et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)

Add to Collection

Article Gastroenterology & Hepatology

Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study

Palak J. Trivedi et al.

GUT (2016)

Add to Collection

Article Gastroenterology & Hepatology

The UK-PBC Risk Scores: Derivation and Validation of a Scoring System for Long-Term Prediction of End-Stage Liver Disease in Primary Biliary Cholangitis

Marco Carbone et al.

HEPATOLOGY (2016)

Add to Collection

Article Gastroenterology & Hepatology

The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis

J. K. Dyson et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)

Add to Collection

Article Gastroenterology & Hepatology

The Immunogenetics of Autoimmune Cholestasis

Palak J. Trivedi et al.

CLINICS IN LIVER DISEASE (2016)

Add to Collection

Article Gastroenterology & Hepatology

Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score

Vinod S. Hegade et al.

DIGESTIVE DISEASES AND SCIENCES (2016)

Add to Collection

Review Gastroenterology & Hepatology

Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016

Atsushi Tanaka et al.

HEPATOLOGY INTERNATIONAL (2016)

Add to Collection

Article Psychiatry

The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature

Andre F. Carvalho et al.

PSYCHOTHERAPY AND PSYCHOSOMATICS (2016)

Add to Collection

Article Multidisciplinary Sciences

Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis

Ana Lleo et al.

SCIENTIFIC REPORTS (2016)

Add to Collection

Article Gastroenterology & Hepatology

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

Willem J. Lammers et al.

GASTROENTEROLOGY (2015)

Add to Collection

Article Gastroenterology & Hepatology

Fibrates and cholestasis

Nisanne S. Ghonem et al.

HEPATOLOGY (2015)

Add to Collection

Review Gastroenterology & Hepatology

Genome-Wide Association Studies in Primary Biliary Cirrhosis

Aliya F. Gulamhusein et al.

SEMINARS IN LIVER DISEASE (2015)

Add to Collection

Article Gastroenterology & Hepatology

Safety and efficacy of long-term nasobiliary drainage to treat intractable pruritus in cholestatic liver disease

V. J. Appleby et al.

FRONTLINE GASTROENTEROLOGY (2015)

Add to Collection

Article Gastroenterology & Hepatology

Hispanics With Primary Biliary Cirrhosis Are More Likely to Have Features of Autoimmune Hepatitis and Reduced Response to Ursodeoxycholic Acid Than Non-Hispanics

Cynthia Levy et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)

Add to Collection

Article Gastroenterology & Hepatology

Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study

Willem J. Lammers et al.

GASTROENTEROLOGY (2014)

Add to Collection

Review Gastroenterology & Hepatology

Pruritus in Cholestasis: Facts and Fiction

Ulrich Beuers et al.

HEPATOLOGY (2014)

Add to Collection

Article Multidisciplinary Sciences

Meta-Analysis Assessment of GP210 and SP100 for the Diagnosis of Primary Biliary Cirrhosis

Shi-Ling Hu et al.

PLOS ONE (2014)

Add to Collection

Review Gastroenterology & Hepatology

Environmental Factors in Primary Biliary Cirrhosis

Brian D. Juran et al.

SEMINARS IN LIVER DISEASE (2014)

Add to Collection

Article Gastroenterology & Hepatology

Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid

Marco Carbone et al.

GASTROENTEROLOGY (2013)

Add to Collection

Article Gastroenterology & Hepatology

Impact of Primary Biliary Cirrhosis on Perceived Quality of Life: The UK-PBC National Study

George F. Mells et al.

HEPATOLOGY (2013)

Add to Collection

Article Gastroenterology & Hepatology

The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: A prospective study

Marco Carbone et al.

JOURNAL OF HEPATOLOGY (2013)

Add to Collection

Article Endocrinology & Metabolism

Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment The FIELD Study

Ru-Dee Ting et al.

DIABETES CARE (2012)

Add to Collection

Article Endocrinology & Metabolism

Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants

Josyf C. Mychaleckyj et al.

DIABETES CARE (2012)

Add to Collection

Article Gastroenterology & Hepatology

Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis

Christophe Corpechot et al.

HEPATOLOGY (2012)

Add to Collection

Article Gastroenterology & Hepatology

Cholestasis-induced pruritus treated with ultraviolet B phototherapy: An observational case series study

Sofie Decock et al.

JOURNAL OF HEPATOLOGY (2012)

Add to Collection

Article Gastroenterology & Hepatology

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

C. Levy et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)

Add to Collection

Article Gastroenterology & Hepatology

Farnesoid X receptor agonists for primary biliary cirrhosis

Keith D. Lindor

CURRENT OPINION IN GASTROENTEROLOGY (2011)

Add to Collection

Article Medicine, General & Internal

Use of Fibrates in the United States and Canada

Cynthia A. Jackevicius et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)

Add to Collection

Article Gastroenterology & Hepatology

Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis

Teru Kumagi et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)

Add to Collection

Review Surgery

Recurrent Primary Biliary Cirrhosis After Liver Transplantation

M. G. Silveira et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2010)

Add to Collection

Article Gastroenterology & Hepatology

Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis

Christophe Corpechot et al.

JOURNAL OF HEPATOLOGY (2010)

Add to Collection

Review Medicine, General & Internal

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

Min Jun et al.

LANCET (2010)

Add to Collection

Article Gastroenterology & Hepatology

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

Christophe Corpechot et al.

HEPATOLOGY (2008)

Add to Collection

Article Gastroenterology & Hepatology

Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis

Konstantims N. Lazaridis et al.

HEPATOLOGY (2007)

Add to Collection

Review Gastroenterology & Hepatology

The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus

Puneeta Tandon et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)

Add to Collection

Article Gastroenterology & Hepatology

Sertraline as a first-line treatment for cholestatic pruritus

Marlyn J. Mayo et al.

HEPATOLOGY (2007)

Add to Collection

Article Gastroenterology & Hepatology

Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

Minoru Nakamura et al.

HEPATOLOGY (2007)

Add to Collection

Article Gastroenterology & Hepatology

Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: A randomized, double-blind controlled trial

Jayant A. Talwalkar et al.

DIGESTIVE DISEASES AND SCIENCES (2006)

Add to Collection

Article Gastroenterology & Hepatology

Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials

Sandeep Khurana et al.

LIVER INTERNATIONAL (2006)

Add to Collection

Article Gastroenterology & Hepatology

Increased prevalence of primary biliary cirrhosis near superfund toxic waste sites

A Ala et al.

HEPATOLOGY (2006)

Add to Collection

Article Gastroenterology & Hepatology

Effect of oral naltrexone on pruritus in cholestatic patients

Fariborz Mansour-Ghanaei et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2006)

Add to Collection

Article Gastroenterology & Hepatology

Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview-based study of 1032 patients

ME Gershwin et al.

HEPATOLOGY (2005)

Add to Collection

Review Medicine, General & Internal

Medical progress: Primary biliary cirrhosis

MM Kaplan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Add to Collection

Article Gastroenterology & Hepatology

A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue

JJ Theal et al.

HEPATOLOGY (2005)

Add to Collection

Article Gastroenterology & Hepatology

Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment

C Selmi et al.

GASTROENTEROLOGY (2004)

Add to Collection

Article Gastroenterology & Hepatology

Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort

MI Prince et al.

GUT (2004)

Add to Collection

Article Gastroenterology & Hepatology

Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus

B Mullhaupt et al.

HEPATOLOGY RESEARCH (2003)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study

R Terg et al.

JOURNAL OF HEPATOLOGY (2002)

Add to Collection

Article Gastroenterology & Hepatology

Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited

G Paumgartner et al.

HEPATOLOGY (2002)

Add to Collection

Article Gastroenterology & Hepatology

Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients

C Corpechot et al.

GASTROENTEROLOGY (2002)

Add to Collection

Article Gastroenterology & Hepatology

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

C Corpechot et al.

HEPATOLOGY (2000)

Add to Collection

Review Immunology

Primary biliary cirrhosis: an orchestrated immune response against epithelial cells

ME Gershwin et al.

IMMUNOLOGICAL REVIEWS (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.